Two products from Roche took a step closer to the EU market this week after the European Medicines Agency recommended that they should be approved.
The products are Phesgo, a subcutaneously administered fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) for treating HER2-positive breast cancer,...